Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- ASKA, Actavis Create Generic Joint Venture Firm in Japan
November 24, 2008
- Santen to Recover Market Share with Tafluprost
November 24, 2008
- DPC Has Increased Use of Generics in over 60 DPC Hospitals: JHA Survey
November 24, 2008
- Kaken: Artz's Sales Up 9.1% Despite NHI Price Cut of 5.8%
November 24, 2008
- Daiichi Sankyo Ties Up with ArQule for Oncology Therapeutics
November 24, 2008
- Kyorin: First Net Loss due to Withdrawal of Gatifloxacin
November 24, 2008
- R&D NEWS IN BRIEF
November 24, 2008
- Mochida: Forecasts for Both Sales and Profits Revised Upward
November 24, 2008
- Chuikyo Will Continue to Review FPMAJ's Drug Pricing System Reform Proposal: Mr Nagano
November 24, 2008
- Kissei: New Products Make Up for Drop in Sales of Cabaser
November 24, 2008
- Kenporen Generally Satisfied with Improvements of Distribution Business Practices
November 24, 2008
- Adapalene to Promote Treatment of Acne in Japan: Prof. Kawashima
November 17, 2008
- Council to Collect Data from 200,000 Diabetic Nephropathy Patients
November 17, 2008
- 15 Doctors Certified as First Pharmaceutical Physicians
November 17, 2008
- Operating Profits of Top-Eight Domestic Companies Down Due to Aggressive Investments
November 17, 2008
- Sales of Irbesartan Total \2.3 Bil. in First 3 Months
November 17, 2008
- Price Settlement Rate Exceeds the Target of 70%
November 17, 2008
- 99 Generics Included in Nov. NHI Price Listing
November 17, 2008
- Kyowa Kirin to Focus on Both Small Molecules, Antibodies
November 17, 2008
- Merck Serono to Accelerate Domestic Development to Achieve US$500 Mil. Sales
November 17, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…